[go: up one dir, main page]

AR035234A1 - Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento - Google Patents

Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento

Info

Publication number
AR035234A1
AR035234A1 ARP020101318A ARP020101318A AR035234A1 AR 035234 A1 AR035234 A1 AR 035234A1 AR P020101318 A ARP020101318 A AR P020101318A AR P020101318 A ARP020101318 A AR P020101318A AR 035234 A1 AR035234 A1 AR 035234A1
Authority
AR
Argentina
Prior art keywords
alkyl
compounds
pharmaceutical compositions
substituted
group
Prior art date
Application number
ARP020101318A
Other languages
English (en)
Original Assignee
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery filed Critical Pharmacopeia Drug Discovery
Publication of AR035234A1 publication Critical patent/AR035234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aril- y biaril-piperidinas, que comprenden un compuestos, incluyendo enantiómeros, estereoisómeros, rotámeros, tautómeros, racematos y prodrogas de dicho compuesto, y sus sales farmacéuticamente aceptables o solvatos de dicho compuesto o de dicha prodroga, dicho compuesto tiene la estructura general que se muestra en la fórmula (1), en la cual: Ar1 está seleccionado de las porciones de fórmula (2) a (7); Z es una porción seleccionada del grupo que consiste en R4-CO-, R4SO2-, R4N(R2')CO-, R4'-, y R4'-O-C(O)-; R2 es H, alquilo o alquilo (sustituido con cicloalquilo); R2' es H o alquilo; R3 es una porción seleccionada de los grupos que consisten en H, alquilo, cicloalquilo, alquilo (sustituido con cicloalquilo, alcoxi, o CF3), arilalquilo, alquilarilo, tetrahidrofuranilo, tetrahidropiranilo, R8SO2-, y un radical de fórmula (8); n es un número de 1 a 5; R4 es fenilo (sustituido con R7) o fenilalquilo (sustituido en el fenilo con R7); R4' es una porción seleccionada del grupo que consiste en H, alquilo, cicloalquilo, alquilo (sustituido con cicloalquilo, alcoxi, o CF3), arilalquilo, alquilarilo, tetrahidrofuranilo y tetrahidropiranilo; R5 los números 1-4 que pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en R7, fenilo, piridilo, tiofenilo, pirimidinilo, piridazinilo y pirazinilo, pudiendo estar estos sustituidos con R7, así también como los N-óxidos de los precedentemente citados piridilo, pirimidinilo, piridazinilo y pirazinilo; R6 los números 1-4 que pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en H, halógeno, alquilo, OH, alcoxi, NH2, NH-alquilo, N(alquilo)2, CN, CF3, NO2 y CF3O; R7 los números 1-3 que pueden ser iguales o diferentes y están independientemente seleccionados del grupo que consiste en H, halógeno, alquilo, OH, alcoxi, NH2, NH-alquilo, N(alquilo)2, CN, CF3, NO2, CF3O, -NH-C(O)-alquilo, -CH(O), -metilendioxi, -CH2OH, benzofuran-2-ilo, -O(alquilo), -C(O)alquilo, e indolilo; y R8 está seleccionado del grupo consistente en alquilo, arilalquilo, alquilarilo, arilo, -NH(alquilo), y N(alquilo)2; como antagonistas del receptor MCH, métodos para preparar dichos compuestos, composiciones farmacéuticasque contienen uno o más de los compuestos, métodos para preparar las composiciones farmacéuticas que comprenden uno o más de dichos compuestos, y el uso de dichos compuestos que es para la manufactura de un medicamento para el tratamiento, prevención o mejoramiento de una o más enfermedades asociadas con el receptor MCH. Un compuesto ilustrativo de la presente es el que se muestra en la fórmula (9).
ARP020101318A 2001-04-12 2002-04-10 Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento AR035234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28352301P 2001-04-12 2001-04-12

Publications (1)

Publication Number Publication Date
AR035234A1 true AR035234A1 (es) 2004-05-05

Family

ID=23086443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101318A AR035234A1 (es) 2001-04-12 2002-04-10 Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento

Country Status (11)

Country Link
US (1) US6887889B2 (es)
EP (1) EP1377293B1 (es)
JP (2) JP4280073B2 (es)
AR (1) AR035234A1 (es)
AT (1) ATE460163T1 (es)
CA (1) CA2443672C (es)
DE (1) DE60235617D1 (es)
ES (1) ES2340147T3 (es)
MX (1) MXPA03009353A (es)
PE (1) PE20021081A1 (es)
WO (1) WO2002083134A1 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6858619B2 (en) 2001-05-04 2005-02-22 Amgen Inc. Fused heterocyclic compounds
HUP0401656A3 (en) 2001-10-25 2012-05-02 Schering Corp Mch antagonists for the treatment of obesity and pharmaceutical compositions containing them
MXPA04004956A (es) 2001-11-26 2004-08-11 Schering Corp Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central.
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
JP2005532991A (ja) 2002-01-10 2005-11-04 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ
AU2003231388A1 (en) * 2002-04-25 2003-11-10 Sumitomo Pharmaceuticals Co., Ltd. Novel piperidine derivative
AU2003236247A1 (en) * 2002-05-03 2003-11-17 Warner-Lambert Company Llc Bombesin antagonists
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004005256A2 (en) * 2002-07-03 2004-01-15 Glaxo Group Limited Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
ZA200503654B (en) * 2002-11-06 2006-09-27 Amgen Inc Fused heterocyclic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004209505B2 (en) * 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
EP1601664B1 (en) * 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
GB0310724D0 (en) * 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
ATE430741T1 (de) 2003-07-24 2009-05-15 Euro Celtique Sa Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
EP1669350B1 (en) 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
WO2005094514A2 (en) * 2004-03-24 2005-10-13 Merck & Co., Inc. Heteroaryl piperidine glycine transporter inhibitors
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JPWO2005097738A1 (ja) * 2004-04-06 2008-02-28 大日本住友製薬株式会社 新規スルホンアミド誘導体
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
AU2005317846B2 (en) * 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
EP1942893A4 (en) * 2005-10-28 2011-10-12 Merck Sharp & Dohme PIPERIDINE Glycine-TRANSPORTER INHIBITORS
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
ES2398319T3 (es) * 2005-12-28 2013-03-15 Vertex Pharmaceuticals Incorporated Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
US8835437B2 (en) * 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741644C (en) 2008-10-30 2013-05-07 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3189908A1 (en) 2020-08-18 2022-02-24 Stephane L. Bogen Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
GB230714A (en) 1924-08-20 1925-03-19 Frederick Charles Bina Improvements in propeller pencils
US2538107A (en) * 1946-07-30 1951-01-16 Sterling Drug Inc 4 aryl-4-aminomethylpiperidine derivatives and their preparation
GB640168A (en) * 1946-07-30 1950-07-12 Sterling Drug Inc Improvements in or relating to the preparation of 4-aryl-4-aminomethyl-piperidine derivatives
US2634275A (en) * 1951-11-07 1953-04-07 Winthrop Stearns Inc 4-acylamino-1-alkyl-4-phenylpi-peridines and method of making same
NL130088C (es) * 1960-03-14
FR1381445A (fr) * 1963-10-23 1964-12-14 Hoechst Ag Composés de pipéridine et leur préparation
FR1477152A (fr) * 1965-04-23 1967-04-14 Yoshitomi Pharmaceutical Procédé de préparation de dérivés de l'indole
US3455940A (en) * 1965-12-07 1969-07-15 Herbert C Stecker Certain halo and dihalo n-substituted salicylamides
US4069223A (en) * 1977-05-02 1978-01-17 G. D. Searle & Co. 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676054B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717802B1 (fr) 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
SE9404438D0 (sv) * 1994-12-21 1994-12-21 Astra Ab New process
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MX9709278A (es) * 1995-05-29 1998-03-31 Pfizer Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
FR2738245B1 (fr) 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
DE69720051T2 (de) * 1996-12-03 2003-09-04 Banyu Pharmaceutical Co., Ltd. Harnstoffderivate
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2350714A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists

Also Published As

Publication number Publication date
ES2340147T3 (es) 2010-05-31
CA2443672C (en) 2011-03-29
PE20021081A1 (es) 2002-12-18
US6887889B2 (en) 2005-05-03
US20030013720A1 (en) 2003-01-16
JP2009102430A (ja) 2009-05-14
EP1377293B1 (en) 2010-03-10
ATE460163T1 (de) 2010-03-15
CA2443672A1 (en) 2002-10-24
JP4280073B2 (ja) 2009-06-17
DE60235617D1 (de) 2010-04-22
MXPA03009353A (es) 2004-02-12
EP1377293A1 (en) 2004-01-07
JP2004526761A (ja) 2004-09-02
WO2002083134A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
AR035234A1 (es) Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
AR049956A1 (es) DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS.
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
AR034116A2 (es) Derivados de piperazinas y piperidinas con efecto analgesico, composiciones farmaceuticas que los contienen, uso de los mismos para la fabricacion de un medicamento y un proceso para la preparacion de dichos compuestos
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
PA8609201A1 (es) Piridinonas sustituidas
AR054799A1 (es) Derivados de oxindol
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
ECSP045073A (es) Nuevos derivados de piperazina
RU2007101685A (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
AR053773A1 (es) Procedimientos para preparar compuestos de indazol
AR019190A1 (es) Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
AR052549A1 (es) Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure